| Oct 22 |
Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript
|
| Oct 22 |
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
|
| Oct 22 |
Editas reviews path for gene editing therapy to save costs
|
| Oct 22 |
Editas, changing course again, looks to partner lead CRISPR therapy
|
| Oct 22 |
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
|
| Oct 21 |
Editas, Roivant's Genevant to develop gene editing therapies
|
| Oct 21 |
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
|
| Oct 18 |
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
|
| Oct 12 |
Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 64% of the company
|
| Oct 5 |
Editas Medicine Secures $57M Deal for Gene-Editing Technology
|
